CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in incidences of overactive bladder
3.4.1.2. Increase in prevalence of bladder tumors and bladder stones
3.4.1.3. Increase in R&D activities
3.4.2. Restraints
3.4.2.1. Lack of awareness regarding novel therapeutics for overactive bladder
3.4.2.2. Side effects associated with the treatment
3.4.3. Opportunities
3.4.3.1. Growth opportunity in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-Cholinergic Drugs
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Beta-3 adrenergic drugs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Botox
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Idiopathic Bladder Overactivity
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Neurogenic Bladder Overactivity
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: OVERACTIVE BLADDER TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Class
7.2.3. Market size and forecast, by Diseases type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Class
7.2.5.1.3. Market size and forecast, by Diseases type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Class
7.2.5.2.3. Market size and forecast, by Diseases type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Class
7.2.5.3.3. Market size and forecast, by Diseases type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Class
7.3.3. Market size and forecast, by Diseases type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Class
7.3.5.1.3. Market size and forecast, by Diseases type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Class
7.3.5.2.3. Market size and forecast, by Diseases type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Class
7.3.5.3.3. Market size and forecast, by Diseases type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Class
7.3.5.4.3. Market size and forecast, by Diseases type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Class
7.3.5.5.3. Market size and forecast, by Diseases type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Class
7.3.5.6.3. Market size and forecast, by Diseases type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Class
7.4.3. Market size and forecast, by Diseases type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Class
7.4.5.1.3. Market size and forecast, by Diseases type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Class
7.4.5.2.3. Market size and forecast, by Diseases type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Class
7.4.5.3.3. Market size and forecast, by Diseases type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Class
7.4.5.4.3. Market size and forecast, by Diseases type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Class
7.4.5.5.3. Market size and forecast, by Diseases type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Class
7.4.5.6.3. Market size and forecast, by Diseases type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Class
7.5.3. Market size and forecast, by Diseases type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Class
7.5.5.1.3. Market size and forecast, by Diseases type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Class
7.5.5.2.3. Market size and forecast, by Diseases type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Korea
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Class
7.5.5.3.3. Market size and forecast, by Diseases type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Class
7.5.5.4.3. Market size and forecast, by Diseases type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. AbbVie Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Alembic Pharmaceuticals Limited
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Astellas Pharma Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Dr. Reddy’s Laboratories Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Pfizer Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Sumitomo Pharma Co., Ltd
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Teva Pharmaceutical Industries Limited
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Cipla Ltd
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Lupin
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Sun Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
TABLE 01. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 02. OVERACTIVE BLADDER TREATMENT MARKET FOR ANTI-CHOLINERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 03. OVERACTIVE BLADDER TREATMENT MARKET FOR BETA-3 ADRENERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 04. OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2021-2031 ($MILLION)
TABLE 05. OVERACTIVE BLADDER TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 07. OVERACTIVE BLADDER TREATMENT MARKET FOR IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
TABLE 08. OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
TABLE 09. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 10. OVERACTIVE BLADDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 11. OVERACTIVE BLADDER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 12. OVERACTIVE BLADDER TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 16. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 17. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 19. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 20. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 21. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 22. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 23. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 24. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 26. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 27. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 28. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 29. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 32. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 33. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 36. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 39. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 42. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 44. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 45. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 48. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 53. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 54. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 55. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 56. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 57. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 58. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 60. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 61. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 64. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 65. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 66. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 67. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 71. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 72. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 73. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 74. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 75. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 76. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 77. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 80. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 86. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. ABBVIE INC.: KEY EXECUTIVES
TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 91. ABBVIE INC.: KEY STRATERGIES
TABLE 92. ALEMBIC PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 93. ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 94. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 95. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 96. ALEMBIC PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 97. ASTELLAS PHARMA INC.: KEY EXECUTIVES
TABLE 98. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 99. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
TABLE 100. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 101. ASTELLAS PHARMA INC.: KEY STRATERGIES
TABLE 102. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
TABLE 103. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 104. DR. REDDY’S LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 105. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 106. DR. REDDY’S LABORATORIES LTD.: KEY STRATERGIES
TABLE 107. PFIZER INC.: KEY EXECUTIVES
TABLE 108. PFIZER INC.: COMPANY SNAPSHOT
TABLE 109. PFIZER INC.: PRODUCT SEGMENTS
TABLE 110. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 111. SUMITOMO PHARMA CO., LTD: KEY EXECUTIVES
TABLE 112. SUMITOMO PHARMA CO., LTD: COMPANY SNAPSHOT
TABLE 113. SUMITOMO PHARMA CO., LTD: PRODUCT SEGMENTS
TABLE 114. SUMITOMO PHARMA CO., LTD: PRODUCT PORTFOLIO
TABLE 115. SUMITOMO PHARMA CO., LTD: KEY STRATERGIES
TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 121. CIPLA LTD: KEY EXECUTIVES
TABLE 122. CIPLA LTD: COMPANY SNAPSHOT
TABLE 123. CIPLA LTD: PRODUCT SEGMENTS
TABLE 124. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 125. LUPIN: KEY EXECUTIVES
TABLE 126. LUPIN: COMPANY SNAPSHOT
TABLE 127. LUPIN: PRODUCT SEGMENTS
TABLE 128. LUPIN: PRODUCT PORTFOLIO
TABLE 129. LUPIN: KEY STRATERGIES
TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 132. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 133. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
